Use of AI Plus One Radiologist Noninferior for Detecting Breast Cancer
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 18, 2023 -- Double reading of screening mammograms by one radiologist plus artificial intelligence (AI) is noninferior to standard-of-care double reading by two radiologists, according to a study published online Sept. 8 in The Lancet Digital Health.
Karin Dembrower, M.D., from Capio Sankt Göran Hospital in Stockholm, and colleagues examined how AI affects cancer detection and false-positive findings in a real-world setting involving women participating in population-based screening. The primary outcome was screen-detected cancer within three months of mammography. Noninferiority of double reading by one radiologist plus AI was compared to standard-of-care double reading by two radiologists in the primary analysis.
A total of 55,581 women aged 40 to 74 years were included in the study from April 1, 2021, to June 9, 2022. The researchers found that based on an initial positive read, 269 women (0.5 percent) were diagnosed with screen-detected breast cancer. For cancer detection, double reading by one radiologist plus AI was noninferior to double reading by two radiologists (261 versus 250; 0.5 versus 0.4 percent detected cases). Compared with double reading by two radiologists, single reading by AI (246 versus 250; 0.4 versus 0.4 percent detected cases) and triple reading by two radiologists plus AI (269 versus 250; 0.5 versus 0.4 percent detected cases) were also noninferior.
"It's clear to us that for screening mammography, one AI-supported radiologist is a better alternative than two radiologists without AI," coauthor Fredrik Strand, M.D., from the Karolinska Institutet in Stockholm, said in a statement.
One author disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.